Grifols announces signing of private offering of EUR 1 billion senior secured notes due 2030

Barcelona, Spain, April 23, 2024 – Grifols (“the Company”) (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced today the successful signing subject to customary closing conditions of the private offering of EUR 1 billion of 7.5% senior secured notes due April 2030 (“the Notes”).

The full proceeds from this transaction will be used to redeem Grifols' Senior Unsecured Notes due in 2025. The features and terms of these Notes are significantly consistent with the Company’s existing senior secured documentation including with respect to collateral and guarantors.

This transaction marks a significant financial milestone, underscoring the financial markets' confidence in Grifols' solid business and operational resilience. This proactive financial strategy not only represents a significant step towards addressing the Company’s 2025 maturities but also fortifies the Company’s long-term financial framework.

“We are extremely pleased with the seamless signing of this transaction, which reflects the strength of our business and the confidence the debt market has in our financial health. This placement not only enhances our capital structure but also reinforces our ongoing commitment to innovation and leadership in the healthcare industry.” said Thomas Glanzmann, Executive Chairman of Grifols.

The Notes will not be registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Advisors

Grifols has been advised by Osborne Clarke and Proskauer Rose LLP. Deutsche Bank has acted as placement agent to the Company.

Further Strategic Developments:

At the same time, Grifols is progressing towards the finalization of divesting a 20% stake in Shanghai RAAS to the Haier Group for USD 1.8 billion. This strategic partnership is on track for completion in the first half of 2024. The proceeds from this divestiture will be applied towards reducing Grifols' secured debt obligations due in 2025, further enhancing its financial stability.